Tata Institute for Genetics and Society (TIGS) – Company Profile

Background

Established in 2017 by the Tata Trusts, the Tata Institute for Genetics and Society (TIGS) is a non-profit research institution dedicated to leveraging advanced genetic and genomic technologies to address critical challenges in human health and agriculture. Operating from its primary facility within the Institute for Stem Cell Science and Regenerative Medicine (inStem) in Bengaluru, Karnataka, TIGS is part of the Bangalore Life Science Cluster (BLiSC), which also includes the National Centre for Biological Sciences (NCBS) and the Centre for Cellular and Molecular Platforms (C-CAMP). This strategic positioning fosters a collaborative environment for cutting-edge research and innovation.

Key Strategic Focus

TIGS concentrates on three primary areas:

1. Infectious Diseases: Developing strategies to combat vector-borne diseases such as malaria, dengue, and chikungunya through innovative vector control methods and environmental surveillance.

2. Rare Genetic Disorders: Creating affordable diagnostic and therapeutic solutions for rare genetic conditions prevalent in India, aiming to enhance accessibility and affordability.

3. Crop Improvement: Utilizing genome-editing technologies to develop resilient and high-yield crop varieties, particularly focusing on rice, to ensure food security and support sustainable agriculture.

Financials and Funding

TIGS was founded through generous seed funding from the Tata Trusts, one of India's oldest philanthropic organizations. This funding supports both TIGS-India and its collaborative counterpart, TIGS-UC San Diego, facilitating research initiatives aimed at addressing health-related issues in India.

Pipeline Development

TIGS is actively engaged in several research projects:

• Vector Control Strategies: Developing ecologically responsible methods to control mosquito populations, thereby reducing the incidence of vector-borne diseases.

• Antimicrobial Resistance (AMR) Surveillance: Implementing environmental surveillance systems to monitor and mitigate the spread of antimicrobial resistance.

• Genome-Edited Crops: Collaborating with rice breeders to create disease-resistant and nutrient-enhanced rice varieties using genome-editing techniques.

Technological Platform and Innovation

TIGS leverages advanced genetic and genomic technologies to drive its research initiatives:

• Genome Editing: Utilizing CRISPR-Cas9 and other genome-editing tools to develop therapeutic interventions for genetic disorders and to enhance crop resilience.

• Environmental Surveillance: Employing high-throughput sequencing and bioinformatics to monitor pathogen prevalence and antimicrobial resistance in various environments.

Leadership Team

• Dr. Rakesh Mishra: Director of TIGS, overseeing the institute's strategic direction and research initiatives.

• Dr. Suresh Subramani: Global Director of TIGS and Distinguished Professor of Molecular Biology at the University of California, San Diego, providing leadership and guidance for TIGS's global operations.

Leadership Changes

In 2021, Dr. Rakesh Mishra assumed the role of Director at TIGS, bringing extensive experience in molecular biology and genetics to the institute.

Competitor Profile

Market Insights and Dynamics

India's biotechnology sector is experiencing rapid growth, with projections estimating its value to reach $150 billion by 2025 and surpass $300 billion by 2030. This expansion is driven by advancements in genetic research, increasing demand for healthcare solutions, and the need for sustainable agricultural practices.

Competitor Analysis

Key competitors in the Indian biotechnology landscape include:

• Institute of Genomics and Integrative Biology (IGIB): A constituent laboratory of the Council of Scientific and Industrial Research (CSIR), focusing on genomics and integrative biology research.

• National Centre for Biological Sciences (NCBS): Specializes in fundamental research across various biological disciplines, contributing to the broader understanding of biological systems.

• Institute of Chemical Technology (ICT): Engages in research and development in chemical engineering and technology, including pharmaceutical sciences.

Strategic Collaborations and Partnerships

TIGS has established several strategic partnerships to enhance its research capabilities:

• AIIMS Bhopal: In May 2024, TIGS signed a Memorandum of Understanding with AIIMS Bhopal to collaborate on research and innovation in genetics and environmental health.

• National Centre for Biological Sciences (NCBS): In December 2021, TIGS announced an institutional alliance with NCBS to address fundamental and applied questions in human health and agriculture.

Operational Insights

TIGS's integration within the Bangalore Life Science Cluster provides access to a collaborative ecosystem, enhancing its research output and translational capabilities. The institute's focus on applying cutting-edge genetic technologies to societal challenges positions it uniquely in the Indian biotechnology sector.

Strategic Opportunities and Future Directions

Looking ahead, TIGS aims to:

• Expand Research Initiatives: Broaden its research portfolio to include additional genetic disorders and crop species.

• Enhance Collaborative Networks: Strengthen existing partnerships and establish new collaborations with academic and industry partners.

• Promote Capacity Building: Develop training programs to build expertise in genetic research and its applications among Indian scientists.

Contact Information

• Website: [Website URL]

• Social Media:

• LinkedIn: [LinkedIn URL]

• Twitter: [Twitter URL]

• Facebook: [Facebook URL]

TIGS continues to advance its mission of applying genetic and genomic research to address pressing societal challenges, contributing significantly to the fields of human health and agriculture in India.